News & Events

Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study

Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study

Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer

Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer

Recent Findings from Naoki Haratake and Co-Authors Yields New Data on Drug Research (M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant...

Recent Findings from Naoki Haratake and Co-Authors Yields New Data on Drug Research (M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant...

Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer

Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer

A dual-arm peptide vaccine against KRAS, EGFR, PD-L1 and VEGFR2 for non-small cell lung cancer in Vietnamese patients

A dual-arm peptide vaccine against KRAS, EGFR, PD-L1 and VEGFR2 for non-small cell lung cancer in Vietnamese patients

KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says

KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says

Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC

Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer

Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer

Silexion reports new preclinical immune data for SIL204 in KRAS cancers

Silexion reports new preclinical immune data for SIL204 in KRAS cancers